Fugazi Research calls Stablecoin Development Corporation stock uninvestable

Fugazi Research calls Stablecoin Development Corporation stock uninvestable

The short-focused research shop says the former NovaBay Pharmaceuticals is a SKY token holding company with no real operating business

Fugazi Research has published a report on Stablecoin Development Corporation, and it does not mince words.

In the report, released October 5, 2026, the firm labels the stock (ticker: SDEV) “uninvestable at any price above zero.”

The core complaint is simple. According to Fugazi, a company with “stablecoin” in its name has no stablecoin infrastructure and no operating business. What it mostly has is a very large pile of SKY tokens.

A token treasury wearing a corporate costume

As of October 2, 2026, SDEV held around 2.32 billion SKY tokens. Fugazi says that stake represents approximately 10% of the token’s total supply.

The report puts the fair value of those holdings at about $180 million as of September 30. That is a notable jump from $119.2 million at the end of June 2026.

Advertisement

In Q2 2026, SDEV earned $2.2 million in staking rewards from its SKY position, with no significant operating revenue reported, according to the findings.

Fugazi also flagged liquidity concerns tied to the size of SDEV’s SKY position. A holder that large may struggle to exit without moving the price against itself.

How a pharma company became a token vault

SDEV did not start life as a crypto play. The company was previously NovaBay Pharmaceuticals before rebranding and beginning to trade under the SDEV ticker on the NYSE American in April 2026.

The pivot was funded through a $134 million private placement in January 2026. Only $25 million of that came in as actual cash. Through the placement, SDEV acquired roughly 943.6 million SKY tokens and $51 million in stablecoins.

Fugazi’s report zeroes in on who supplied those assets. The CEO of SDEV’s linked fund contributed 74% of the tokens in the private placement, according to the findings.

Fugazi pointed to significant ownership concentration and several potential conflicts of interest as part of its case against the stock.

The dilution and volume problem

A pending S-3 registration could enable the resale of 212.9 million shares. Per the findings, that equals 4x the current outstanding share count.

Second, SDEV’s own disclosures include warnings that wash trading could be inflating its reported trading volumes. Fugazi highlighted this as a red flag.

What this means for SDEV holders and the treasury trade

For existing shareholders, the report bundles several distinct risks into one place. There is concentration risk in a single token, potential dilution from the S-3 resale registration, governance concerns around the private placement, and questions about how real the trading volume is.

The SKY exposure cuts both ways. The rise in fair value from $119.2 million in June to about $180 million in September shows how quickly the balance sheet can swell when the token rallies. A company with no meaningful operating revenue has little cushion if the token’s price falls, and staking rewards of $2.2 million a quarter would not go far against a large drawdown.

The next things to watch are whether the S-3 registration becomes effective, how SDEV responds to the report, and how the SKY token’s value moves in the weeks ahead.

Disclosure: This article was edited by John Chen. For more information on how we create and review content, see our Editorial Policy.
Fugazi Research calls Stablecoin Development Corporation stock uninvestable
Fugazi Research calls Stablecoin Development Corporation stock uninvestable

The short-focused research shop says the former NovaBay Pharmaceuticals is a SKY token holding company with no real operating business

Share

Add us on Google

Fugazi Research has published a report on Stablecoin Development Corporation, and it does not mince words.

In the report, released October 5, 2026, the firm labels the stock (ticker: SDEV) “uninvestable at any price above zero.”

The core complaint is simple. According to Fugazi, a company with “stablecoin” in its name has no stablecoin infrastructure and no operating business. What it mostly has is a very large pile of SKY tokens.

A token treasury wearing a corporate costume

As of October 2, 2026, SDEV held around 2.32 billion SKY tokens. Fugazi says that stake represents approximately 10% of the token’s total supply.

The report puts the fair value of those holdings at about $180 million as of September 30. That is a notable jump from $119.2 million at the end of June 2026.

Advertisement

In Q2 2026, SDEV earned $2.2 million in staking rewards from its SKY position, with no significant operating revenue reported, according to the findings.

Fugazi also flagged liquidity concerns tied to the size of SDEV’s SKY position. A holder that large may struggle to exit without moving the price against itself.

How a pharma company became a token vault

SDEV did not start life as a crypto play. The company was previously NovaBay Pharmaceuticals before rebranding and beginning to trade under the SDEV ticker on the NYSE American in April 2026.

The pivot was funded through a $134 million private placement in January 2026. Only $25 million of that came in as actual cash. Through the placement, SDEV acquired roughly 943.6 million SKY tokens and $51 million in stablecoins.

Fugazi’s report zeroes in on who supplied those assets. The CEO of SDEV’s linked fund contributed 74% of the tokens in the private placement, according to the findings.

Fugazi pointed to significant ownership concentration and several potential conflicts of interest as part of its case against the stock.

The dilution and volume problem

A pending S-3 registration could enable the resale of 212.9 million shares. Per the findings, that equals 4x the current outstanding share count.

Second, SDEV’s own disclosures include warnings that wash trading could be inflating its reported trading volumes. Fugazi highlighted this as a red flag.

What this means for SDEV holders and the treasury trade

For existing shareholders, the report bundles several distinct risks into one place. There is concentration risk in a single token, potential dilution from the S-3 resale registration, governance concerns around the private placement, and questions about how real the trading volume is.

The SKY exposure cuts both ways. The rise in fair value from $119.2 million in June to about $180 million in September shows how quickly the balance sheet can swell when the token rallies. A company with no meaningful operating revenue has little cushion if the token’s price falls, and staking rewards of $2.2 million a quarter would not go far against a large drawdown.

The next things to watch are whether the S-3 registration becomes effective, how SDEV responds to the report, and how the SKY token’s value moves in the weeks ahead.

Disclosure: This article was edited by John Chen. For more information on how we create and review content, see our Editorial Policy.